tecarfarin

Description: Tecarfarin (ATI5923) is a potent, non-competitive and orally bioavailable vitamin K epoxide reductase (VKOR) inhibitor with antithrombotic activity by impairing the activation of the vitamin K-dependent clotting factors II, VII, IX and X. Like warfarin, tecarfarin attenuates venous and arterial thrombus formation in animal models by reducing the levels of the vitamin K-dependent coagulation factors. ecarfarin, via a vitamin K-dependent mechanism, causes changes in key parameters of haemostasis in beagle dogs that are consistent with effective anticoagulation. Compared to warfarin it has a decreased potential to interact metabolically with drugs that inhibit CYP450 enzymes and, therefore, may offer an improved safety profile for patients.

References:

1. Hobl EL, et al. Tecarfarin: A Novel Vitamin K Antagonist. Thromb Haemost. 2017 Nov; 117(11):2009-2011.

2.BowersoxSS, et al. Antithrombotic activity of the novel oral anticoagulant, Tecarfarin Sodium 3-4-((1, 1, 1, 3, 3, 3-hexafluoro-2-methylpropan-2-yloxy)carbonyl) benzyl-2-oxo-2H-chromen-4-olate in animal models. ThrombRes. 2010 Nov; 126(5):e383-8.